Hydroxyzine Hydrochloride 25mg Tablets are a tablet form pharmaceutical that contains Hydroxyzine Hydrochloride to deliver the effect required when given at the therapeutic dose. Hydroxyzine Hydrochloride 25mg Tablets are a produced in a controlled formulation and tablet manufacture to ensure that adequate dispersion of the API is obtained and the tablet has consistent characteristics between individual tablets and across production batches. If you are a pharmaceutical marketer expanding a portfolio into solid oral dosage forms then Hydroxyzine Hydrochloride 25mg Tablets can be integrated into a professional PCD Pharma Franchise portfolio.
The formulation will be prepared as an appropriate mixture of API and pharmaceutical excipients that are agreed upon following the definitive dosage-form design. Efforts in product development include raw-material specification and qualification, calculation of accurate dispensation, homogenous mixing, suitable compression properties, finished-product specifications and testing, stability testing and appropriate packaging.
The initial preparation of Hydroxyzine Hydrochloride for incorporation into a finished formulation will use a material of pharmaceutical grade that has been tested for compliance with formulation specifications. Prior to manufacture all relevant specifications of the active material are checked such as identification, assay, purity, moisture content, particle characteristics and related requirements.
Accurate dispensation will be required to balance the dosage-strength of 25 mg per unit with the total quantity prepared. Appropriate weighing devices, and procedures will be adopted to minimize error, and to provide a traceable material-control process from receipt to storage.
The selection of excipients is made based on their physical and manufacturing characteristics and formulated in line with the finalized formulation to optimize their contribution to the finished tablet. This may involve flow-control, binding, compression, disintegration, lubrication and integrity of the resulting dosage form.
The compatibility of the API and excipient mixture may be investigated and documented during formulation development. The composition of the final formulation is retained according to the decided formulation.
Following dispensation then mixing of the API and excipients is performed to ensure that each component is distributed as homogeneously as possible. The protocol for processing then depends on the final formulation, and may be through direct compression, dry-granulation or wet-granulation steps.
Where required, granulation can increase flow or cohesiveness of the mixture prior to compression. To ensure homogeneity then it is preferable to undertake premixing or geometric dilution steps during formulation development.
Subsequently the granulate is dried, milled and sized if necessary and lubricated for tablet manufacturing. During processing each stage will be monitored to optimize conditions for homogeneity.
In-process evaluation then includes blend uniformity, moisture content, particle-size distribution, and flow characteristics before the material proceeds to compression.
The granulate or otherwise prepared powder blend can then be compressed using tablet-making equipment designed for a defined range of mass and characteristic characteristics including weight, thickness, and hardness, friability, etc.
Tablet weights are checked at defined series of tablets during manufacture to check variation, hardness can be tested to ensure the strength of the matrix, thickness can be checked as a tablet dimension and friability can be used to assess their resistance to handling.
Visual inspection can be used to note defects such as cracks, chips, cut surfaces, surface roughness, uneven appearance, etc., and if a film-coat is part of the formulation then spray rate, coating weight-gain, temperature and drying time can be optimized during the manufacturing process.
Manufacturing equipment must be calibrated, cleaned and maintained according to a set procedure, and batch-records keeping will include formulation details and raw-material usage, identification of equipment, yields, and in-process data.
Each stage of manufacture is in-process tested to assure that the finished dosage-form will have the characteristics in compliance with specifications established in development. Raw-materials, in-process materials, and finished-formulations may all be tested as part of a suitable product-control regime.
Applicable tests include identification, assay, related-substances, dissolution, disintegration, average weight, weight variation, hardness, friability and the physical appearance of the tablet. In addition, dosage-unit uniformity testing will be performed where appropriate.
Validation and verification of assay and related-substances procedures is part of testing. Calibrated laboratory apparatus, control measures with testing reference standards, set procedures and documented results comprise the quality program.
Stability tests, according to a defined schedule, are performed to enable evaluation of the product over the proposed shelf life. Factors such as appearance, assay, related-substances, dissolution and physical characteristics are considered in stability testing.
Packaging may be chosen as a means of maintaining the quality of a solid oral product by protecting it from the environment and handling damage during transportation and storage. Suitable strip or blister packaging may be selected, and designs and materials tested for their contribution to this goal.
Secondary packaging forms a further line of protection and should be designed to show all important information relating to expiry date, manufacture, composition, storage requirement, labeling and storage conditions.
If you operate a PCD Pharma Franchise then the incorporation of Hydroxyzine Hydrochloride 25mg Tablets into a professional portfolio of solid oral dosage forms will involve the coordinated development of formulating, manufacturing, testing, packaging, and distributions.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech